AGRYLIN

This brand name is authorized in Brazil, Canada, Hong Kong, Japan, New Zealand, Singapore, United States, South Africa

Active ingredients

The drug AGRYLIN contains one active pharmaceutical ingredient (API):

1 Anagrelide UNII VNS4435G39 - ANAGRELIDE HYDROCHLORIDE ANHYDROUS

Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production. Read about Anagrelide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AGRYLIN Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX35	Anagrelide	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX35

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501121020037717, 531600101111318
Country: CA	Health Products and Food Branch	Identifier(s): 02236859
Country: HK	Department of Health Drug Office	Identifier(s): 51737
Country: JP	医薬品医療機器総合機構	Identifier(s): 4299003M1020
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 14499
Country: SG	Health Sciences Authority	Identifier(s): 12525P
Country: US	FDA, National Drug Code	Identifier(s): 54092-063
Country: ZA	Health Products Regulatory Authority	Identifier(s): 33/8/0289